Zerumbone, a natural cyclic sesquiterpene of Zingiber zerumbet Smith, attenuates nonalcoholic fatty liver disease in hamsters fed on high-fat diet

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Tzeng, Thing Fong ^a   Liou, Shorong Shii ^a   Chang, Chia Ju ^a   Liu, I Min ^a  

^a TAJEN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A DESATURASE 1; CARNITINE PALMITOYLTRANSFERASE I; CHOLESTEROL; FATTY ACID SYNTHASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; ZERUMBONE;

ANIMAL TISSUE; ARTICLE; ATTENUATION; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; FEEDING BEHAVIOR; HEPATITIS; HOMEOSTASIS; INSULIN RESISTANCE; LIPID DIET; LIVER; LIVER WEIGHT; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STEATOSIS; TREATMENT DURATION; TREATMENT OUTCOME; ZINGIBER ZERUMBET;

EID: 84886703028     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/303061     Document Type: Article

References (35)

1. Angulo P., GI epidemiology: nonalcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2007 25 8 883 889 2-s2.0-34547732002
2. Paschos P., Paletas K., Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009 13 1 9 19 2-s2.0-65749115425
3. Rzouq F. S., Volk M. L., Hatoum H. H., Talluri S. K., Mummadi R. R., Sood G. K., Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. American Journal of the Medical Sciences 2010 340 2 89 93 2-s2.0-77956025285 10.1097/MAJ.0b013e3181e15da8
4. Chan S. M., Sun R. Q., Zeng X. Y., Choong Z. H., Wang H., Watt M. J., Ye J. M., Activation of PPAR α ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress. Diabetes 2013 62 6 2095 2105
5. Jacobson T. A., Myopathy with statin-fibrate combination therapy: clinical considerations. Nature Reviews Endocrinology 2009 5 9 507 518 2-s2.0-70349334010 10.1038/nrendo.2009.151
6. Osborne T. F., Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action. The Journal of Biological Chemistry 2000 275 42 32379 32382 2-s2.0-0034693259
7. Eberlé D., Hegarty B., Bossard P., Ferré P., Foufelle F., SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 2004 86 11 839 848 2-s2.0-10044271037 10.1016/j.biochi.2004.09.018 (Pubitemid 39602764)
8. Schreuder T. C., Verwer B. J., van Nieuwkerk C. M., Mulder C. J., Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. World Journal of Gastroenterology 2008 14 16 2474 2486 2-s2.0-47849087880 10.3748/wjg.14.2474 (Pubitemid 352037734)
9. Yob N. J., Jofrry S. M., Affandi M. M., Teh L. K., Salleh M. Z., Zakaria Z. A., Zingiber zerumbet (L.) Smith: a review of its ethnomedicinal, chemical, and pharmacological uses. Evidence-based Complementary and Alternative Medicine 2011 2011 12 2-s2.0-79959194493 10.1155/2011/543216 543216
10. Dai J. R., Cardellina J. H. II, McMahon J. B., Boyd M. R., Zerumbone, an HIV-inhibitory and cytotoxic sesquiterpene of Zingiber aromaticum and Z. zerumbet. Natural Product Letters 1997 10 2 115 118 2-s2.0-0030812283 (Pubitemid 27292336)
11. Kirana C., McIntosh G. H., Record I. R., Jones G. P., Antitumor activity of extract of Zingiber aromaticum and its bioactive sesquiterpenoid zerumbone. Nutrition and Cancer 2003 45 2 218 225 2-s2.0-0041510434 (Pubitemid 37022796)
12. Huang G. C., Chien T. Y., Chen L. G., Wang C. C., Antitumor effects of zerumbone from Zingiber zerumbet in P-388D1 cells in vitro and in vivo. Planta Medica 2005 71 3 219 224 2-s2.0-16444363611 10.1055/s-2005-837820 (Pubitemid 40476777)
13. Szabolcs A., Tiszlavicz L., Kaszaki J., Pósa A., Berkó A., Varga I. S., Boros I., Szüts V., Lonovics J., Takács T., Zerumbone exerts a beneficial effect on inflammatory parameters of cholecystokinin octapeptide-induced experimental pancreatitis but fails to improve histology. Pancreas 2007 35 3 249 255 2-s2.0-34748873851 10.1097/mpa.0b013e318070d791 (Pubitemid 47482518)
14. Kitayama T., Attractive reactivity of a natural product, zerumbone. Bioscience, Biotechnology and Biochemistry 2011 75 2 199 207 2-s2.0-79952170641 10.1271/bbb.100532
15. Chang C. J., Tzeng T. F., Liou S. S., Chang Y. S., Liu I. M., Regulation of lipid disorders by ethanol extracts from Zingiber zerumbet in high-fat diet-induced rats. Food Chemistry 2012 132 1 460 467 2-s2.0-84355166455 10.1016/j.foodchem.2011.11.022
16. Bhathena J., Kulamarva A., Martoni C., Urbanska A. M., Malhotra M., Paul A., Prakash S., Diet-induced metabolic hamster model of nonalcoholic fatty liver disease. Diabetes, Metabolic Syndrome and Obesity 2011 4 195 203
17. Lieber C. S., Leo M. A., Mak K. M., Xu Y., Cao Q., Ren C., Ponomarenko A., DeCarli L. M., Model of nonalcoholic steatohepatitis. American Journal of Clinical Nutrition 2004 79 3 502 509 2-s2.0-1242290584 (Pubitemid 41115597)
18. Van Heek M., Compton D. S., France C. F., Tedesco R. P., Fawzi A. B., Graziano M. P., Sybertz E. J., Strader C. D., Davis H. R. Jr., Diet-induced obese mice develop peripheral, but not central, resistance to leptin. The Journal of Clinical Investigation 1997 99 3 385 390 2-s2.0-0030807358 (Pubitemid 27414794)
19. Friedewald W. T., Levy R. I., Fredrickson D. S., Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 1972 18 6 499 502 2-s2.0-0015348189
20. Matthews D. R., Hosker J. P., Rudenski A. S., Naylor B. A., Treacher D. F., Turner R. C., Homeostasis model assessment: insulin resistance and β -cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 7 412 419 2-s2.0-0021813187 (Pubitemid 15018832)
21. Folch J., Lees M., Sloane-Stanley G. H., A simple method for the isolation and purification of total lipides from animal tissues. The Journal of Biological Chemistry 1957 226 1 497 509 2-s2.0-70449158340
22. Livak K. J., Schmittgen T. D., Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001 25 4 402 408 2-s2.0-0035710746 10.1006/meth.2001.1262 (Pubitemid 34164012)
23. Thomas E. L., Hamilton G., Patel N., O'Dwyer R., Doré C. J., Goldin R. D., Bell J. D., Taylor-Robinson S. D., Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005 54 1 122 127 2-s2.0-10844240700 10.1136/gut.2003.036566 (Pubitemid 40007230)
24. Jaskiewicz K., Rzepko R., Sledzinski Z., Fibrogenesis in fatty liver associated with obesity and diabetes mellitus type 2. Digestive Diseases and Sciences 2008 53 3 785 788 2-s2.0-39849107896 10.1007/s10620-007-9942-x (Pubitemid 351317095)
25. Fatani S., Itua I., Clark P., Wong C., Naderali E. K., The effects of diet-induced obesity on hepatocyte insulin signaling pathways and induction of non-alcoholic liver damage. International Journal of General Medicine 2011 4 211 219 2-s2.0-79953123741 10.2147/IJGM.S17376
26. Braunersreuther V., Viviani G. L., Mach F., Montecucco F., Role of cytokines and chemokines in non-alcoholic fatty liver disease. World Journal of Gastroenterology 2012 18 8 727 735 2-s2.0-84857550029 10.3748/wjg.v18.i8.727
27. Mao J., DeMayo F. J., Li H., Abu-Elheiga L., Gu Z., Shaikenov T. E., Kordari P., Chirala S. S., Heird W. C., Wakil S. J., Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis. Proceedings of the National Academy of Sciences of the United States of America 2006 103 22 8552 8557 2-s2.0-33744781581 10.1073/pnas.0603115103 (Pubitemid 43838493)
28. Jensen-Urstad A. P., Semenkovich C. F., Fatty acid synthase and liver triglyceride metabolism: housekeeper or messenger? Biochimica et Biophysica Acta 2012 1821 5 747 753 2-s2.0-84859161710 10.1016/j.bbalip.2011.09.017
29. Dobrzyn A., Ntambi J. M., The role of stearoyl-CoA desaturase in the control of metabolism. Prostaglandins, Leukotrienes and Essential Fatty Acids 2005 73 1 35 41 2-s2.0-20444484914 10.1016/j.plefa.2005.04.011 (Pubitemid 40826926)
30. Rector R. S., Payne R. M., Ibdah J. A., Mitochondrial trifunctional protein defects: clinical implications and therapeutic approaches. Advanced Drug Delivery Reviews 2008 60 13-14 1488 1496 2-s2.0-51249110143 10.1016/j.addr.2008.04.014
31. Cherkaoui-Malki M., Surapureddi S., El-Hajj H. I., Vamecq J., Andreoletti P., Hepatic steatosis and peroxisomal fatty acid beta-oxidation. Current Drug Metabolism 2012 13 10 1412 1421
32. Bartlett K., Eaton S., Mitochondrial β -oxidation. European Journal of Biochemistry 2004 271 3 462 469 2-s2.0-0842287450 10.1046/j.1432-1033.2003. 03947.x (Pubitemid 38183621)
33. Poirier Y., Antonenkov V. D., Glumoff T., Hiltunen J. K., Peroxisomal β -oxidation-a metabolic pathway with multiple functions. Biochimica et Biophysica Acta 2006 1763 12 1413 1426 2-s2.0-33845326985 10.1016/j.bbamcr.2006. 08.034 (Pubitemid 44883386)
34. Reddy J. K., Hashimoto T., Peroxisomal β -oxidation and peroxisome proliferator activated receptor α: an adaptive metabolic system. Annual Review of Nutrition 2001 21 193 230 2-s2.0-0034939632 10.1146/annurev.nutr.21.1. 193 (Pubitemid 32695270)
35. Huang J., Jia Y., Fu T., Viswakarma N., Bai L., Rao M. S., Zhu Y., Borensztajn J., Reddy J. K., Sustained activation of PPAR α by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice. FASEB Journal 2012 26 2 628 638 2-s2.0-84856531460 10.1096/fj.11-194019